ADRB1 and Sepsis: One study investigated the effect of the β1-AR antagonist esmolol on sepsis with the preclinical CLP model in rats, revealing that esmolol improved survival, reduced intraperitoneal TNF-α concentrations and E. coli translocation to draining lymph nodes, and prevented damage to the gut mucosa [115].